CGTLive®’s Weekly Rewind – December 12, 2025

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FasTCAR Manufactured BCMAxCD19 CAR T-cell Therapy Shows Promise for Multiple Myeloma

AZD0120, a dual-targeted CAR T-cell therapy, shows high efficacy in treating relapsed multiple myeloma, achieving a 96% response rate.

2. Janna Minehart, MD, on Hematology-Oncology Immunotherapy Highlights at ASH 2025

The clinical fellow in hematology/oncology at the University of Pennsylvania discussed several sessions she's excited about at the ASH Annual Meeting.

3. FDA Approves Waskyra as First Gene Therapy for Wiskott-Aldrich Syndrome

The Fondazione Telethon agent, etuvetidigene autotemcel, significantly reduced severe infections and bleeding events in clinical studies.

4. Crawford Strunk, MD, on Integrating Gene Therapy into Clinical Care for Sickle Cell Disease

The associate staff member at the Cleveland Clinic discussed the institution's experience with integrating use of exa-cel and lovo-cel.

5. MDA 2026 to Bring Keynote Insights and Evolving Neuromuscular Care

Sharon Hesterlee, PhD, the chief research officer of the Muscular Dystrophy Association, discussed the upcoming conference and the evolving therapeutic landscape in neuromuscular disease.